BR0307906A - Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2 - Google Patents

Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2

Info

Publication number
BR0307906A
BR0307906A BR0307906-6A BR0307906A BR0307906A BR 0307906 A BR0307906 A BR 0307906A BR 0307906 A BR0307906 A BR 0307906A BR 0307906 A BR0307906 A BR 0307906A
Authority
BR
Brazil
Prior art keywords
alpha
inhibitor
combinations
delta
selective cyclooxygenase
Prior art date
Application number
BR0307906-6A
Other languages
English (en)
Inventor
Charles Price Taylor Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0307906A publication Critical patent/BR0307906A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMBINAçõES DE UM LIGANDO ALFA-2-DELTA COM UM INIBIDOR SELETIVO DE CICLOOXIGENASE-2". A presente invenção refere-se a uma combinação compreendendo um inibidor seletivo de COX-2, ou um seu sal farmaceuticamente aceitável, e um ligando Alfa-2-delta, ou um seu sal farmaceuticamente aceitável, e valdecoxib. Exemplos de inibidores seletivos de COX-2 incluem, valdecoxib, rofecoxib e celecoxib. Exemplos de ligandos Alfa-2-delta incluem gabapentina, pregabalina, ácido (3S,4S)-(1-aminometil-3,4-dimetilciclopentil)-acético e cloridrato de 3-(1-aminometilciclohexilmetil)-4H-[1,2,4]oxadiazol5-ona. As combinações são úteis para o tratamento de certas doenças incluindo lesão da cartilagem, inflamação, dor e artrite.
BR0307906-6A 2002-02-22 2003-02-12 Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2 BR0307906A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19
PCT/IB2003/000534 WO2003070237A1 (en) 2002-02-22 2003-02-12 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
BR0307906A true BR0307906A (pt) 2004-12-21

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307906-6A BR0307906A (pt) 2002-02-22 2003-02-12 Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2

Country Status (21)

Country Link
US (1) US20030199567A1 (pt)
EP (1) EP1480639A1 (pt)
JP (1) JP2005523281A (pt)
KR (1) KR20040085216A (pt)
CN (1) CN1635887A (pt)
AR (1) AR038531A1 (pt)
AU (1) AU2003246864A1 (pt)
BR (1) BR0307906A (pt)
CA (1) CA2476438A1 (pt)
CO (1) CO5611109A2 (pt)
HN (1) HN2003000071A (pt)
IL (1) IL162932A0 (pt)
MX (1) MXPA04008175A (pt)
NO (1) NO20043947L (pt)
PA (1) PA8567201A1 (pt)
PE (1) PE20031052A1 (pt)
PL (1) PL372210A1 (pt)
RU (1) RU2286151C2 (pt)
TW (1) TW200303214A (pt)
UY (1) UY27675A1 (pt)
WO (1) WO2003070237A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054560A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
NZ545494A (en) * 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
AR060404A1 (es) * 2006-04-11 2008-06-11 Novartis Ag Compuestos organicos utiles como inhibidores de dipeptidil-peptidasa iv
US20130012485A1 (en) * 2006-12-22 2013-01-10 Baeschlin Daniel Kaspar Organic compounds
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
SI2735338T1 (sl) * 2008-09-05 2019-04-30 Grunenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
JP2023548380A (ja) * 2020-10-28 2023-11-16 トレモー・ファーマシューティカルズ・インコーポレイテッド 非水溶性ｃｏｘ－２阻害の水性製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
RU2168982C2 (ru) * 1994-07-27 2001-06-20 Варнер-Ламберт Компани Способ лечения состояния страха или лечения и/или предупреждения состояния паники, очищенный белок, способный связывать габапентин, и фармацевтическая композиция, обладающая успокоительным, противопаническим и противосудорожным действием
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
CA2304967C (en) * 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
JP2003516353A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション ヴァルデコキシブ組成物

Also Published As

Publication number Publication date
PE20031052A1 (es) 2003-12-24
PL372210A1 (en) 2005-07-11
AR038531A1 (es) 2005-01-19
MXPA04008175A (es) 2004-11-26
EP1480639A1 (en) 2004-12-01
IL162932A0 (en) 2005-11-20
CO5611109A2 (es) 2006-02-28
HN2003000071A (es) 2003-11-24
AU2003246864A1 (en) 2003-09-09
CA2476438A1 (en) 2003-08-28
RU2286151C2 (ru) 2006-10-27
CN1635887A (zh) 2005-07-06
PA8567201A1 (es) 2003-11-12
KR20040085216A (ko) 2004-10-07
WO2003070237A1 (en) 2003-08-28
US20030199567A1 (en) 2003-10-23
NO20043947L (no) 2004-09-21
RU2004125609A (ru) 2006-01-27
UY27675A1 (es) 2003-09-30
JP2005523281A (ja) 2005-08-04
TW200303214A (en) 2003-09-01

Similar Documents

Publication Publication Date Title
BR0307906A (pt) Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2
Li et al. Citrullinated histone H3: a novel target for the treatment of sepsis
AU2003301109A8 (en) Pharmaceutical compositions and method of treating Parkinson's disease
DK1443967T3 (da) Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
BRPI0418244A (pt) composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
EA200100905A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
EP1627639A3 (en) Use of COX-2 inhibitors for the treatment of affective disorders
BRPI0720500A8 (pt) Preparação líquida transdérmica
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
EA200501019A1 (ru) Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
BRPI0412424A (pt) composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα
EA200500941A1 (ru) Средство для лечения болезней суставов
Eren et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids
BRPI0415628A (pt) suspensões analgésicas para liberação controlada
Barzkar et al. Jellyfish protein hydrolysates: Multifunctional bioactivities unveiled in the battle against diabetes, inflammation, and bacterial pathogenesis
EP2286807A3 (en) Medicament for preventive and/or therapeutic treatment of adhesion of bowel
BR0312943A (pt) Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
BRPI0415630A (pt) suspensões analgésicas para liberação controlada
BR0312744A (pt) Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com um inibidor selectivo da ciclooxigenase-2, à excepção do celecoxib ou valdecoxib
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
EP1652525A4 (en) ANTI-VIRUS CORONA DRUG

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/42; A61P 29/00

Ipc: A61K 31/42 (2011.01), A61P 29/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.